Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Zeldox Prolongs QT Interval 30 To 60 Msec In 11.6% Of Patients

Executive Summary

The oral formulation of Pfizer's Zeldox is associated with a QT prolongation of 30 to 60 milliseconds in 11.6% of patients, an update of Swedish labeling for the atypical antipsychotic states.

You may also be interested in...

Pfizer Expects Zeldox Labeling Negotiations To Continue Past September

Pfizer expects an "approvable" action from FDA in September to set up a final round of negotiations over labeling for the antipsychotic Zeldox, Pfizer Global R&D President John Niblack indicated during a July 27 investor conference call.

Zeldox QTc Prolongation Is Less Severe Than Serlect, Pfizer Tells Committee

The QTc prolongation associated with Pfizer's antipsychotic Zeldox does not lead to the same clinical events as seen with Abbott/Lundbeck's antipsychotic Serlect, Pfizer told the Psychopharmacological Drugs Advisory Committee July 19.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts